Clinical Trials Browser

INDUSTRY × Expanded_access × Stomach Neoplasms × Clear all

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Available

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT04681248 2025-08-03

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

No longer available

GastrointestinalGynecologicSarcoma

Carcinoma, Squamous Cell, Carcinosarcoma, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT02065765 2025-01-09

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Approved for marketing

Gastrointestinal

Stomach Neoplasms

NCT02307812 2025-01-09

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Approved for marketing

Gastrointestinal

Stomach Neoplasms